This company has been marked as potentially delisted and may not be actively trading. LogicBio Therapeutics (LOGC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsBuy This Stock LOGC vs. MYTE, BWMX, VGII, OG, WNW, OGBLY, HEPS, PTLO, ETD, and BHShould you be buying LogicBio Therapeutics stock or one of its competitors? The main competitors of LogicBio Therapeutics include MYT Netherlands Parent B.V. (MYTE), Betterware de México, S.A.P.I. de C.V. (BWMX), Virgin Group Acquisition Corp. II (VGII), Onion Global (OG), Meiwu Technology (WNW), Onion Global (OGBLY), D-MARKET Electronic Services & Trading (HEPS), Portillo's (PTLO), Ethan Allen Interiors (ETD), and Biglari (BH). LogicBio Therapeutics vs. Its Competitors MYT Netherlands Parent B.V. Betterware de México, S.A.P.I. de C.V. Virgin Group Acquisition Corp. II Onion Global Meiwu Technology Onion Global D-MARKET Electronic Services & Trading Portillo's Ethan Allen Interiors Biglari MYT Netherlands Parent B.V. (NYSE:MYTE) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap retail/wholesale companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment. Do insiders & institutionals believe in MYTE or LOGC? 10.1% of MYT Netherlands Parent B.V. shares are held by institutional investors. Comparatively, 46.1% of LogicBio Therapeutics shares are held by institutional investors. 1.9% of MYT Netherlands Parent B.V. shares are held by company insiders. Comparatively, 8.1% of LogicBio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to MYTE or LOGC? In the previous week, LogicBio Therapeutics had 3 more articles in the media than MYT Netherlands Parent B.V.. MarketBeat recorded 3 mentions for LogicBio Therapeutics and 0 mentions for MYT Netherlands Parent B.V.. MYT Netherlands Parent B.V.'s average media sentiment score of 0.00 equaled LogicBio Therapeutics'average media sentiment score. Company Overall Sentiment MYT Netherlands Parent B.V. Neutral LogicBio Therapeutics Neutral Do analysts prefer MYTE or LOGC? MYT Netherlands Parent B.V. presently has a consensus price target of $14.00, indicating a potential upside of 76.32%. Given MYT Netherlands Parent B.V.'s stronger consensus rating and higher possible upside, equities analysts clearly believe MYT Netherlands Parent B.V. is more favorable than LogicBio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MYT Netherlands Parent B.V. 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00LogicBio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation and earnings, MYTE or LOGC? MYT Netherlands Parent B.V. has higher revenue and earnings than LogicBio Therapeutics. MYT Netherlands Parent B.V. is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMYT Netherlands Parent B.V.$881.44M0.77-$26.95M-$0.43-18.47LogicBio Therapeutics$287M0.67-$317M-$5.79-1.26 Is MYTE or LOGC more profitable? MYT Netherlands Parent B.V. has a net margin of -3.98% compared to LogicBio Therapeutics' net margin of -141.03%. MYT Netherlands Parent B.V.'s return on equity of -5.88% beat LogicBio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MYT Netherlands Parent B.V.-3.98% -5.88% -3.63% LogicBio Therapeutics -141.03%-81.98%-52.13% Which has more volatility and risk, MYTE or LOGC? MYT Netherlands Parent B.V. has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. SummaryMYT Netherlands Parent B.V. beats LogicBio Therapeutics on 10 of the 15 factors compared between the two stocks. Get LogicBio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LOGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LOGC vs. The Competition Export to ExcelMetricLogicBio TherapeuticsCatalog & mail IndustryRetail SectorNASDAQ ExchangeMarket Cap$192.11M$312.66M$26.79B$9.61BDividend YieldN/A7.87%172.88%4.14%P/E Ratio-1.263.1927.3524.84Price / Sales0.6712.2612.5898.65Price / CashN/A58.4757.5258.36Price / Book0.823.775.465.64Net Income-$317M$4.74M$874.58M$265.68M LogicBio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LOGCLogicBio Therapeutics1.2528 of 5 stars$7.31-1.2%N/A+37.3%$192.11M$287M-1.2662News CoverageMYTEMYT Netherlands Parent B.V.1.4372 of 5 stars$8.23+0.5%$14.00+70.1%+118.7%$705.30M$881.44M-19.141,240News CoverageBWMXBetterware de México, S.A.P.I. de C.V.3.4982 of 5 stars$12.52+14.2%N/A-5.9%$408.99M$14.17B8.941,270Dividend IncreaseHigh Trading VolumeVGIIVirgin Group Acquisition Corp. IIN/A$1.46-2.7%N/A-7.2%$73.46MN/A0.00N/AOGOnion GlobalN/AN/AN/AN/A$25.02M$2.04B0.00796WNWMeiwu TechnologyN/A$1.85-1.1%N/A-89.4%$5.86M$158.49K0.0050OGBLYOnion GlobalN/AN/AN/AN/A$11KN/A0.00860HEPSD-MARKET Electronic Services & Trading1.695 of 5 stars$2.49-0.8%$3.50+40.6%+0.5%$806.67M$1.74B-15.563,743High Trading VolumePTLOPortillo's3.564 of 5 stars$10.22-3.4%$14.00+37.0%-27.9%$791.55M$710.55M23.777,450Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionETDEthan Allen Interiors3.0885 of 5 stars$29.78-0.3%$30.00+0.7%-3.1%$759.34M$646.22M13.243,404BHBiglari0.8431 of 5 stars$313.45-1.9%N/A+45.1%$727.14M$362.11M-1.422,535News CoverageEarnings Report Related Companies and Tools Related Companies MYT Netherlands Parent B.V. Alternatives Betterware de México, S.A.P.I. de C.V. Alternatives Virgin Group Acquisition Corp. II Alternatives Onion Global Alternatives Meiwu Technology Alternatives Onion Global Alternatives D-MARKET Electronic Services & Trading Alternatives Portillo's Alternatives Ethan Allen Interiors Alternatives Biglari Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LOGC) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
